Biotechnology industries

Biological products

Kivu Bioscience Presents Promising Preclinical Data for KIVU-107 ADC at 16th World ADC San Diego

Kivu Bioscience, a biotechnology company developing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, has announced the presentation of new preclinical activity and safety data for KIVU-107, a best-in-class PTK7-targeting ADC, at the 16th World ADC San Diego conference. The data highlight the unique biophysical and therapeutic properties of KIVU-107, showcasing